Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Common Stock

Last Annual Value

41.09K

3-Year CAGR

21%

5-Year CAGR

28%

10-Year CAGR

13%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Common Stock

ANEB · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
41.09K
17.0%12.0%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
1.00K
-57.5%-30.1%N/A
5.30K
38.4%32.0%N/A
69.00K
-0.5%8.9%N/A
98.00K
15.9%28.5%15.1%
7.00K
20.5%18.5%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
8.00
10.1%-7.8%N/A
1.00K
N/AN/AN/A
472.00K
-0.9%2.2%11.6%
44.00K
0.8%8.0%N/A
0.00
N/AN/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72